Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter retrospective study to assess outcomes of pembrolizumab as first line treatment in patients with non-small cell lung cancer and very high PD-L1 expression

Next Previous
Trial Profile

A multicenter retrospective study to assess outcomes of pembrolizumab as first line treatment in patients with non-small cell lung cancer and very high PD-L1 expression

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 31 May 2020 Results evaluating clinical outcomes to first-line pembrolizumab in patients with advanced NSCLC, a PD-L1 tumor proportion score (TPS) of >50%, and an ECOG PS of 2 presented at the 56th Annual Meeting of the American Society of Clinical Oncology
  • 28 Aug 2019 New trial record
  • 12 Aug 2019 Results published in the Annals of Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top